Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846257 | 0.82 | MAPT (0.49) | MAPTLMNATSHRSLC6A3SLC6A4 | |
| SCHEMBL3478477 | 0.82 | TSHR (0.56) | MAPTLMNATSHRALDH1A1HSD17B10 | |
| SCHEMBL31536078 | 0.81 | MAPT (0.48) | MAPTLMNATSHRSLC6A3ALDH1A1 | |
| SCHEMBL1247973 | 0.81 | MAPT (0.48) | MAPTLMNATSHRSLC6A3ALDH1A1 | |
| SCHEMBL11300004 | 0.79 | ALDH1A1 (0.53) | MAPTLMNATSHRSLC6A3SLC6A4 | |
| SCHEMBL1324559 | 0.79 | PKM (0.36) | MAPTLMNATSHRSLC6A3ALDH1A1 | |
| SCHEMBL29361206 | 0.79 | MAPT (0.43) | MAPTLMNATSHRSLC6A3SLC6A4 | |
| SCHEMBL1249661 | 0.79 | MAPT (0.43) | MAPTLMNATSHRSLC6A3SLC6A4 | |
| SCHEMBL2940686 | 0.78 | ALDH1A1 (0.47) | MAPTLMNATSHRALDH1A1KDM4E | |
| SCHEMBL31267844 | 0.78 | MAPT (0.39) | MAPTLMNATSHRSLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695241-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20260034113-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| CN-120077028-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024213082-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-10-17 | — | — | WO | disclosed |
| CN-118055930-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024099337-A1 | THIADIAZOLYL DERIVATIVES, COMPOSITIONS, AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-16 | — | — | WO | disclosed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| EP-4251618-A1 | 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Sage Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023061415-A1 | THIADIAZOLYL DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2023-04-20 | — | — | WO | disclosed |
| EP-3644990-B1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2022-11-30 | — | — | EP | disclosed |
| WO-2022115620-A1 | 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-10981902-B2 | 5-(pyridin-3-yl)oxazole allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3644990-A1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | Merck Sharp & Dohme Corp. (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200109137-A1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2020-04-09 | — | — | US | disclosed |
| WO-2019000238-A1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019005589-A1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109137-A1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | CHRM5, CHRM4, CHRM3 | MAPT 876/4885LMNA 4465/4885TSHR 153/4885 |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | MAPT 306/4885LMNA 2941/4885TSHR 4693/4885 |
| US-10981902-B2 | 5-(pyridin-3-yl)oxazole allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM5, CHRM4, CHRM3 | MAPT 876/4885LMNA 4465/4885TSHR 153/4885 |
| US-20260034113-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | SRD5A2, NR3C2, SRD5A1 | MAPT 2257/4885LMNA 3259/4885TSHR 97/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | MAPT 2934/4885LMNA 1281/4885TSHR 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.